ATG7 and breast cancer: Given that in the previous in vivo trial, DCA demonstrated the highest therapeutic efficacy against PI3Ki-resistant cells when used as a single agent (Fig. 6b), we proceeded to test the response of ATG7-knockout cells to DCA in the orthotopic breast cancer xenograft model, following the same experimental design (Fig. 7a).